ImmunityBio’s ANKTIVA Gains European Approval, Stock Surges 31%
ImmunityBio's shares soared over 31% following the European Commission's conditional approval of ANKTIVA, marking the first authorized immunotherapy for BCG-unresponsive non-muscle invasive bladder cancer in Europe. The treatment, used alongside BCG, offers an alternative to radical bladder removal for patients across 30 European countries.
The approval expands ANKTIVA's reach to 33 countries, including prior clearances in the U.S., UK, and Saudi Arabia. Clinical trial results showed a 71% complete response rate, with 84% of responders avoiding cystectomy at 36 months—a significant advancement in bladder cancer care.
Despite posting 1,025% revenue growth, ImmunityBio remains unprofitable with $82.56 million in trailing revenue. The stock has surged more than 200% year-to-date, reflecting investor Optimism about ANKTIVA's commercial potential.
